2020 Anti-Doping Testing Figures / World Anti-Doping Agency (WADA). - Montreal : WADA, 2021
Contents:
- Executive Summary - pp. 2-9 (7 pages)
- Laboratory Report -– pp. 10-36 (27 pages)
- Sport Report - pp. 37-137 (101 pages)
- Testing Authority Report - pp. 138-244 (107 pages)
- ABP Report-Blood Analysis - pp. 245-279 (35 pages)
Report Highlights:
- A 46% decrease in the overall number of samples analyzed: 278,047 in 2019 to 149,758 in 2020.
- A decrease in the total percentage of Adverse Analytical Findings (AAFs): 0.97% in 2019 (2,702 AAFs from 278,047 samples) to 0.67% in 2020 (1,009 AAFs from 149,758 samples).
- All WADA-accredited Laboratories saw a decrease in the total number of samples recorded.
- A decrease in the total number and percentage of non-Athlete Biological Passport (ABP) blood samples analyzed: 9.1% in 2019 (25,339 of 278,047) and 7.3% (10,940 of 149,758) in 2020.
- A decrease of 38% in the number of ABP blood samples tested: 36,401 in 2019 to 22,666 in 2020.
The World Anti-Doping Agency (WADA) has publishes its 2020 Testing Figures Report (2020 Report), which summarizes the results of all the samples WADA-accredited Laboratories analyzed and reported in WADA’s Anti-Doping Administration and Management System (ADAMS) in 2020.
This is the sixth and last set of global testing figures under the 2015 World Anti-Doping Code (Code) that came into effect in January 2015. The 2020 Report – which includes an Executive Summary and sub-reports by Laboratory, Sport, Testing Authority and Athlete Biological Passport (ABP) Blood Analysis – includes in- and out-of-competition urine samples; blood and ABP blood data; and, the resulting Adverse Analytical Findings (AAFs) and Atypical Findings (ATFs).
